Please assess the completion status of the following clinical trial:

Trial Title: Short Duration High Intensity Intrapleural Alteplase With Pulmozyme in Pleural Infection Management

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patient with age more than 17 year old~* evidence of complex parapneumonic effusion or empyema; with poor pleural fluid drainage of ≤150 mL after 24 hours of insertion of chest drain~* clinical evidence of infection such as fever and or elevated C-reactive protein (CRP) or white-cell count~* complex pleural effusion proven by ultrasound~* pleural fluid analysis that fulfilled at least one of the characteristics: frank pus, exudative nature (according to light's criteria), gram stain or culture positive, lactate dehydrogenase (LDH) \> 1000 U/L, pH \< 7.2 and/or glucose level \< 3.3mmol/L~Exclusion Criteria:~* known allergy to pulmozyme or alteplase~* acute stroke, active bleeding diathesis~* major surgery in past 5 days~* previous pneumonectomy on the infected side~* bronchopleural fistula~* pregnancy~* coagulopathy (INR \> 2, APTT \>100, platelet count \< 50,000 cells)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Intra-pleural Alteplase 16mg with Pulmozyme (DNase) 5mg for total 3 doses within 24 hours~Intervention Drug: Combination Alteplase and pulmozyme (DNase)

Based on this trial design, predict the completion outcome and termination type (if applicable).